We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Confirms Agreement With CMS’ Restrictive ESA Policy
FDA Confirms Agreement With CMS’ Restrictive ESA Policy
November 9, 2007
During a conference call announcing new warnings and revised indications for erythropoiesis-stimulating agents (ESAs), the FDA repeated a previous statement that the Centers for Medicare & Medicaid Services’ (CMS) new restrictive reimbursement policy for the antianemia agents is consistent with approved physician labeling.